860296-14-6

Basic information

• Product Name: 3-chloro-4-fluoro-2-hydroxybenzoic acid
• Synonyms: 3-chloro-4-fluoro-2-hydroxybenzoic acid
• CAS NO: 860296-14-6
• Molecular Weight: 190.558
• Mol File: 860296-14-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-chloro-4-fluoro-2-hydroxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-4-fluoro-2-hydroxybenzoic acid(860296-14-6)
• EPA Substance Registry System: 3-chloro-4-fluoro-2-hydroxybenzoic acid(860296-14-6)

Safety Data

• Hazardous Substances Data: 860296-14-6(Hazardous Substances Data)

Upstream product

• 372-20-3 3-fluorophenol 
• 154257-75-7 2,4-difluoro-3-chlorobenzoic acid 
• 126940-10-1 1-fluoro-3-(methoxy-methoxy)benzene 
• 860296-13-5 2-chloro-1-fluoro-3-(methoxymethoxy)benzene 
• 124-38-9 carbon dioxide 

Relevant articles and documents

TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS

Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.